Ventyx Biosciences (VTYX)
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 14.000
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 25.000
- Volume Ratio
- 0.00
- Turnover Ratio
- --
Ventyx Biosciences Analyst Rating
View moreForecast & Rating
Jan 8, 2026Price forecast
$14.141.02%
Forecast & RatingHold
8analysts
- Strong buy12.50%
- Buy0.00%
- Hold87.50%
- Sell0.00%
- Strong sell0.00%
News
- StockTitan · Apr 21 at 07:35 AM
Vext Announces Revised Date for Q4 and Fiscal 2025 Financial Results Release | VEXTF Stock News
- Tip Ranks · Mar 4 at 08:49 AM
Ventyx Biosciences Completes Cash Merger and Equity Payout
- TradingView · Mar 4 at 08:23 AM
Ventyx Biosciences directors and officers swapped under merger; Anderson, Haug, Davis join board
- TradingView · Mar 4 at 08:23 AM
Ventyx Biosciences Announced Transfer or Voluntary Withdrawal of Listing
- Market Beat · Feb 22 at 04:21 AM
242,229 Shares in Ventyx Biosciences, Inc. $VTYX Acquired by GSA Capital Partners LLP
- prnewswire · Feb 4 at 09:00 PM
22:00 ETHalper Sadeh LLC Encourages STEL, GORO, SKYT, VTYX Shareholders to Contact the Firm to Discuss Their Rights
